RU2447060C2 - Ингибиторы сфингозинкиназы - Google Patents

Ингибиторы сфингозинкиназы Download PDF

Info

Publication number
RU2447060C2
RU2447060C2 RU2008100606/04A RU2008100606A RU2447060C2 RU 2447060 C2 RU2447060 C2 RU 2447060C2 RU 2008100606/04 A RU2008100606/04 A RU 2008100606/04A RU 2008100606 A RU2008100606 A RU 2008100606A RU 2447060 C2 RU2447060 C2 RU 2447060C2
Authority
RU
Russia
Prior art keywords
chlorophenyl
carboxylic acid
adamantane
ethyl
adamantan
Prior art date
Application number
RU2008100606/04A
Other languages
English (en)
Other versions
RU2008100606A (ru
Inventor
Чарльз Д. СМИТ (US)
Чарльз Д. СМИТ
Кевин Дж. ФРЕНЧ (US)
Кевин Дж. ФРЕНЧ
Ян ЖУАНГ (US)
Ян ЖУАНГ
Original Assignee
Эпоуджи Биотекнолоджи Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпоуджи Биотекнолоджи Корпорейшн filed Critical Эпоуджи Биотекнолоджи Корпорейшн
Publication of RU2008100606A publication Critical patent/RU2008100606A/ru
Application granted granted Critical
Publication of RU2447060C2 publication Critical patent/RU2447060C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/39—Unsaturated compounds containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/26—Unsaturated compounds having a carboxyl group bound to a seven-to-twelve-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/45—Monoamines
    • C07C211/48—N-alkylated amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/52—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C215/76—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/06—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/49—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/59—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/62—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/56—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and doubly-bound oxygen atoms bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/29—Saturated compounds containing keto groups bound to rings
    • C07C49/313—Saturated compounds containing keto groups bound to rings polycyclic
    • C07C49/323—Saturated compounds containing keto groups bound to rings polycyclic having keto groups bound to condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/527—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings
    • C07C49/563—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/527—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings
    • C07C49/567—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/527—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings
    • C07C49/573—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings containing hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/40—Unsaturated compounds containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/753—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of polycyclic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/30—Nitrogen atoms non-acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Image Processing (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Настоящее изобретение к новым соединениям формулы I или их фармацевтически приемлемым солям, обладающим способностью ингибировать сфингозинкиназу, к фармацевтической композиции на их основе, к способу ингибирования сфингозинкиназы и к способу лечения заболеваний, выбранных из рака молочной железы, диабетической ретинопатии, артрита и колита.
Figure 00000108
,
где X представляет собой -C(R3,R4)N(R5)-, -C(O)N(R4)-; R1 представляет собой фенил, незамещенный или замещенный 1 или 2 галогенами. Значения заместителей R2, R3, R4, R5 такие, как указаны в формуле изобретения. 4 н. и 13 з.п. ф-лы, 9 табл., 18 ил., 26 пр.

Description

Текст описания приведен в факсимильном виде.
Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105
Figure 00000106
Figure 00000107

Claims (17)

1. Соединение формулы I
Figure 00000108

или его фармацевтически приемлемая соль, где
X представляет собой -C(R3,R4)N(R5)-, -C(O)N(R4)-;
R1 представляет собой фенил, незамещенный или замещенный 1 или 2 галогенами;
R2 представляет собой (С3-С6)циклоалкил, фенил, (С1-С6)алкилфенил, (С2-С6)алкенилфенил, (С2-С6)алкенилнафтил, гетероарил, выбранный из бензооксазолила, бензотиазолила, индолила, тетразолила, карбазолила и пуринила, (С1-С6)алкилгетероарила, где гетероарил выбран из бензодиоксолила, пиридила, имидазолила, карбазолила и тиенила, 6-членный гетероциклоалкил, содержащий 1 или 2 атома азота в качестве гетероатомов, (С1-С6)алкилгетероциклоалкил, где гетероциклоалкил представляет собой 5-членный гетероциклоалкил, содержащий 1 атом азота, в качестве гетероатома, который необязательно замещен оксогруппой, или 6-членный гетероциклоалкил, содержащий 2 гетероатома, выбранных из азота и кислорода, -моно(С1-С6)алкиламино(С1-С6)алкил, -(С1-С6)алкил-S-(С1-С6)алкил, -тиазолилфенил, -тиенилфенил, (С2-С6)алкенилгетероарил, где гетероарил выбран из пиридила, имидазолила и карбазолила, или (С2-С6)алкенилтиенилфенил;
R3 представляет собой Н или (С1-С6)алкил;
где алкил и кольцевая часть каждой из указанных выше R2 групп является необязательно замещенной вплоть до 5 группами, которые независимо представляют собой (С1-С6)алкил, галоген, галоген(С1-С6)алкил, -ОС(O)(С1-С6алкил), -С(O)O(С1-С6алкил), -CF3, -OCF3, -ОН, (С1-С6)алкокси, гидрокси(С1-С6)алкил, -CN, -S-(С1-С6)алкил, -SO2R′ или NR′R″, и где каждая алкильная часть заместителя является дополнительно необязательно замещенной 1, 2 или 3 группами, независимо выбранными из CN, ОН, NH2; и
R4 и R5 независимо представляют собой Н или (С1-С6)алкил,
где R′ и R″ независимо представляют собой Н или (С1-С6)алкил,
2. Соединение по п.1, где R2 представляет собой (С2-С6)алкенилфенил, (С2-С6)алкенилнафтил, (С2-С6)алкенилгетероарил, где гетероарил выбран из пиридила, имидазолила и карбазолила, или -(С2-С6)алкенилтиенилфенил.
3. Соединение по п.1, где R2 представляет собой (С2-С6)алкенилфенил или (С2-С6)алкенилнафтил.
4. Соединение по п.3, где арильная часть (С2-С6)алкенилфенила или (С2-С6)алкенилнафтила необязательно замещена 1 или 2 галогенами, циано или гидрокси.
5. Соединение по п.1, где R2 представляет собой (С3-С6)циклоалкил, фенил, (С1-С6)алкилфенил, гетероарил, выбранный из бензооксазолила, бензотиазолила, индолила, тетразолила, карбазолила и пуринила, (С1-С6)алкилгетероарил, где гетероарил выбран из бензодиоксолила, пиридила, имидазолила, карбазолила и тиенила.
6. Соединение по п.1, где R2 представляет собой фенил или (С1-С6)алкилфенил.
7. Соединение по п.1, где R2 представляет собой гетероарил или (С1-С6)алкилгетероарил.
8. Соединение по п.6 или 7, где арил или гетероарил возможно замещены 1, 2, 3, 4 или 5 группами, независимо выбранными из галогена, гидрокси, алкила, цианоалкила, аминоалкила, трифторметила и алкокси.
9. Соединение по любому из пп.1-8, где X представляет собой -C(R3,R4)N(R5)-.
10. Соединение по п.9, где R3 представляет собой метил и R4 представляет собой Н.
11. Соединение по п.9, где R5 представляет собой Н.
12. Соединение по любому из пп.1-8, где X представляет собой -C(O)N(R4)-.
13. Соединение по п.9, где R4 представляет собой Н.
14. Соединение по п.1, которое представляет собой:
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты циклопропиламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты (2-этилсульфанилэтил)-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты фениламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты (4-гидроксифенил)-амид;
Уксусной кислоты 4-{[3-(4-хлорфенил)-адамантан-1-карбонил]-амино}-фениловый эфир;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты (2,4-дигидроксифенил)-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты (3-гидроксиметил-фенил)-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты (4-цианометил-фенил)-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты бензиламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты 4-трет-бутилбензиламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты 4-метилсульфанилбензиламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты 3-трифторметилбензиламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты 4-трифторметилбензиламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты 3,5-бис-трифторметилбензиламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты 3-фтор-5-трифторметилбензиламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты 2-фтор-4-трифторметилбензиламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты 3,5-дифторбензиламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты 3,4-дифторбензиламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты 3,4,5-трифторбензиламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты 3-хлор-4-фторбензиламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты 4-фтор-3-трифторметилбензиламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты 2-хлор-4-фторбензиламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты 4-хлор-3-трифторметилбензиламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты 3-аминометил-2,4,5,6-тетрахлорбензиламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты [1-(4-хлорфенил)-этил]-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты [1-(4-бромфенил)-этил]-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты 4-метансульфонилбензиламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты 4-диметиламинобензиламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты 4-трифторметоксибензиламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты 3-трифторметоксибензиламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты 3,4-дигидроксибензиламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты фенэтиламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты [2-(4-фторфенил)-этил]-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты [2-(4-бромфенил)-этил]-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты [2-(4-гидроксифенил)-этил]-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты [2-(4-метоксифенил)-этил]-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты [2-(3-бром-4-метоксифенил)-этил]-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты [2-(3,4-дигидроксифенил)-этил]-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты (2-бензо[1,3]диоксол-5-илэтил)-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты (3-фенилпропил)-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты (1-метилпиперидин-4-ил)-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты (4-метилпиперазин-1-ил)-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты (3-трет-бутиламинопропил)-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты (3-пирролидин-1-илпропил)-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты [3-(2-оксопирролидин-1-ил)-пропил]-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты [2-(1-метилпирролидин-2-ил)-этил]-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты (2-морфолин-4-илэтил)-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты (2-пиперазин-1-илэтил)-амид;
3-(4-Фторфенил)-адамантан-1-карбоновой кислоты (пиридин-4-илметил)-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты (пиридин-4-илметил)-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты (2-пиридин-4-илэтил)-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты (3-имидазол-1-илпропил)-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты (2-метил-1Н-индол-5-ил)-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты (1Н-тетразол-5-ил)-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты (9-этил-9Н-карбазол-3-ил)-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты [4-(4-хлорфенил)-тиазол-2-ил]-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты бензотиазол-2-иламид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты (5-хлор-бензооксазол-2-ил)-амид;
3-(4-Хлорфенил)-адамантан-1-карбоновой кислоты (9Н-пурин-6-ил)-амид;
4-{[3-(4-Хлорфенил)-адамантан-1-илметил]-амино}-фенол;
[3-(4-Хлорфенил)-адамантан-1-илметил]-(4-трифторметилбензил)-амин;
[3-(4-Хлорфенил)-адамантан-1-илметил]-(2-фтор-4-трифторметилбензил)-амин;
[3-(4-Хлорфенил)-адамантан-1-илметил]-(4-фтор-3-трифторметилбензил)-амин;
[3-(4-Хлорфенил)-адамантан-1-илметил]-(4-трифторметоксибензил)-амин;
[3-(4-Хлорфенил)-адамантан-1-илметил]-(1-метилпиперидин-4-ил)-амин;
[3-(4-Хлорфенил)-адамантан-1-илметил]-(4-метилпиперазин-1-ил)-амин;
N-трет-Бутил-N′-[3-(4-хлорфенил)-адамантан-1-илметил]-пропан-1,3-диамин;
[3-(4-Хлорфенил)-адамантан-1-илметил]-(3-пирролидин-1-илпропил)-амин;
[3-(4-Хлорфенил)-адамантан-1-илметил]-[2-(1-метилпирролидин-2-ил)-этил]-амин;
[3-(4-Хлорфенил)-адамантан-1-илметил]-(2-морфолин-4-илэтил)-амин;
[3-(4-Хлорфенил)-адамантан-1-илметил]-пиридин-4-илметиламин;
[3-(4-Хлорфенил)-адамантан-1-илметил]-(9-этил-9Н-карбазол-3-ил)-амин;
[3-(4-Хлорфенил)-адамантан-1-илметил]-[5-(4-хлорфенил)-тиазол-2-ил]-амин;
Фенил-[1-(3-фениладамантан-1-ил)-этил]-амин;
{1-[3-(4-Фторфенил)-адамантан-1-ил]-этил}-фениламин;
{1-[3-(4-Хлорфенил)-адамантан-1-ил]-этил}-фениламин;
Бензил-{1-(3-фениладамантан-1-ил)-этил}-амин;
Бензил-{1-[3-(4-фторфенил)-адамантан-1-ил]-этил}-амин;
Бензил-{1-[3-(4-хлорфенил)-адамантан-1-ил]-этил}-амин;
(4-трет-Бутилбензил)-{1-[3-(4-хлорфенил)-адамантан-1-ил]-этил}-амин;
[1-(4-Бромфенил)-этил]-{1-[3-(4-хлорфенил)-адамантан-1-ил]-этил}-амин;
[2-(4-Бромфенил)-этил]-{1-[3-(4-хлорфенил)-адамантан-1-ил]-этил}-амин;
(1-Метилпиперидин-4-ил)-[1-(3-фениладамантан-1-ил)-этил]-амин;
{1-[3-(4-Фторфенил)-адамантан-1-ил]-этил}-(1-метилпиперидин-4-ил)-амин;
{1-[3-(4-Хлорфенил)-адамантан-1-ил]-этил}-(1-метилпиперидин-4-ил)-амин;
{1-[3-(4-Хлорфенил)-адамантан-1-ил]-этил}-(4-метилпиперазин-1-ил)-амин;
{1-[3-(Фенил)-адамантан-1-ил]-этил}-пиридин-4-илметиламин;
{1-[3-(4-Хлорфенил)-адамантан-1-ил]-этил}-(6-хлорпиридин-3-илметил)-амин;
{1-[3-(4-Хлорфенил)-адамантан-1-ил]-этил}-(2-пиридин-4-илэтил)-амин;
{1-[3-(4-Хлорфенил)-адамантан-1-ил]-этил}-(3Н-имидазол-4-илметил)-амин;
{1-[3-(4-Хлорфенил)-адамантан-1-ил]-этил}-(2-метил-1Н-индол-5-ил)-амин;
{1-[3-(4-Хлорфенил)-адамантан-1-ил]-этил}-(9-этил-9Н-карбазол-3-ил)-амин;
{1-[3-(4-Хлорфенил)-адамантан-1-ил]-этил}-(9-этил-9Н-карбазол-3-илметил)-амин;
(4-Бромтиофен-2-илметил)-{1-[3-(4-хлорфенил)-адамантан-1-ил]-этил}-амин;
или их фармацевтически приемлемые соли.
15. Фармацевтическая композиция, обладающая способностью ингибировать сфингозинкиназу, содержащая эффективное количество соединения по любому из п.1-14 или его фармацевтически приемлемой соли в комбинации с фармацевтически приемлемым носителем, средой или вспомогательным агентом.
16. Способ ингибирования сфингозинкиназы, включающий введение эффективного количества соединения по любому из пп.1-14 или его фармацевтически приемлемой соли или композиции по п.15.
17. Способ лечения заболевания, выбранного из рака молочной железы, диабетической ретинопатии, артрита и колита, включающий введение терапевтически эффективного количества соединения или соли по любому из пп.1-14 или композиции по п.15.
RU2008100606/04A 2005-06-17 2006-06-15 Ингибиторы сфингозинкиназы RU2447060C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69156305P 2005-06-17 2005-06-17
US60/691,563 2005-06-17

Publications (2)

Publication Number Publication Date
RU2008100606A RU2008100606A (ru) 2009-07-27
RU2447060C2 true RU2447060C2 (ru) 2012-04-10

Family

ID=37106302

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008100606/04A RU2447060C2 (ru) 2005-06-17 2006-06-15 Ингибиторы сфингозинкиназы

Country Status (14)

Country Link
US (4) US7338961B2 (ru)
EP (2) EP2314574A1 (ru)
JP (1) JP5368789B2 (ru)
KR (1) KR101386282B1 (ru)
CN (1) CN101248041B (ru)
AU (1) AU2006261327B2 (ru)
BR (1) BRPI0611966B1 (ru)
CA (1) CA2612338C (ru)
ES (1) ES2528451T3 (ru)
IL (1) IL187881A (ru)
MX (1) MX2007015863A (ru)
RU (1) RU2447060C2 (ru)
WO (1) WO2006138660A2 (ru)
ZA (1) ZA200800423B (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2529201C1 (ru) * 2013-06-18 2014-09-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный технический университет" (ВолгГТУ) Способ получения n-(2-гетероциклоалкил-1-илэтил)адамантан-2-аминов
RU2605698C1 (ru) * 2015-12-23 2016-12-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный технический университет" (ВолгГТУ) Производные 2-(адамант-2-ил)этиламина, обладающие потенциальной противовирусной активностью

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
CA2585775C (en) 2004-10-29 2013-10-01 Musc Foundation For Research Development Cationic ceramides, and analogs thereof, and their use for preventing or treating cancer
CA2585645C (en) 2004-10-29 2014-10-21 Musc Foundation For Research Development Ceramides and apoptosis-signaling ligand
US8324237B2 (en) * 2005-05-20 2012-12-04 Smith Charles D Methods for the treatment and prevention of inflammatory diseases
US7338961B2 (en) * 2005-06-17 2008-03-04 Apogee Biotechnology Corporation Sphingosine kinase inhibitors
ES2389062T3 (es) * 2006-01-18 2012-10-22 Amgen, Inc Compuestos de tiazol como inhibidores de proteína cinasa B (PKB)
WO2008119017A1 (en) * 2007-03-28 2008-10-02 High Point Pharmaceuticals, Llc 11beta-hsd1 active compounds
AU2008276512A1 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
US8314151B2 (en) 2008-04-29 2012-11-20 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, and processes for using same
US8372888B2 (en) * 2008-04-29 2013-02-12 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, compositions and processes for using same
US20110275673A1 (en) * 2008-09-19 2011-11-10 Yibin Xiang Inhibitors of sphingosine kinase 1
EP2166094A1 (en) 2008-09-23 2010-03-24 Ecole Normale Superieure De Lyon Methods for prolonging the health benefits triggered by a dietary restriction using a sphingosine kinase inhibitor
JP5721631B2 (ja) 2008-11-06 2015-05-20 ムスク ファウンデーション フォー リサーチ デベロップメント 酸性セラミダーゼのリソソーム親和性阻害剤
WO2010105183A1 (en) * 2009-03-12 2010-09-16 Apogee Biotechnology Corporation Sphingosine kinase inhibitor prodrugs
US20120122870A1 (en) * 2009-05-08 2012-05-17 Musc Foundation For Research Development Treatment Of Ischemia-Reperfusion Injury
WO2011020116A1 (en) * 2009-08-14 2011-02-17 University Of Virginia Patent Foundation Imidamide sphingosine kinase inhibitors
EP2513057B1 (de) * 2009-12-14 2013-09-04 Merck Patent GmbH Inhibitoren der sphingosinkinase
WO2012121168A1 (ja) * 2011-03-04 2012-09-13 国立大学法人京都大学 キナーゼ阻害剤
RU2461544C1 (ru) * 2011-04-19 2012-09-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт вирусологии им. Д.И. Ивановского" Министерства здравоохранения и социального развития Российской Федерации Производные 1-(1-адамантил)этиламина и их противовирусная активность
US9688668B2 (en) 2012-02-08 2017-06-27 University Of Virginia Patent Foundation Long chain base sphingosine kinase inhibitors
RU2524216C1 (ru) * 2013-04-09 2014-07-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт вирусологии им. Д.И. Ивановского" Министерства здравоохранения Российской Федерации Пептидные производные 1-(1-адамантил)этиламина и их противовирусное действие
WO2016054261A1 (en) 2014-10-01 2016-04-07 Kevin Lynch Sphingosine kinase inhibitors
EP4134076A1 (en) 2014-10-24 2023-02-15 Redhill Biopharma Ltd. Therapy for inhibition of single-stranded rna virus replication
ES2895850T3 (es) 2014-11-24 2022-02-22 Univ Illinois Procedimiento de prevención o tratamiento de una enfermedad o afección pulmonar
WO2016110595A1 (en) * 2015-01-09 2016-07-14 Atonomics A/S A UNIVERSAL ASSAY FOR DETERMINING THE QUANTITY OF TNFα INHIBITORY DRUGS AND THEIR CORRESPONDING ANTI-DRUG-ANTIBODIES
CN104529859B (zh) * 2015-01-13 2016-08-17 佛山市赛维斯医药科技有限公司 含苯胺和二烯氟代金刚烷结构的化合物、其制备方法和用途
RU2727474C2 (ru) * 2015-10-06 2020-07-21 Редхилл Байофарма Лтд. Виды комбинированной терапии для лечения рака
EP3405183A4 (en) * 2016-01-18 2019-12-11 Arisan Therapeutics Inc. ADAMATE DERIVATIVES FOR TREATING A FILOVIRUS INFECTION
EP3407912B1 (en) 2016-01-28 2022-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for enhancing the potency of the immune checkpoint inhibitors
WO2017172989A1 (en) 2016-03-30 2017-10-05 Thorpe Steven Brandon Sphingosine kinase inhibitor amidoxime prodrugs
CN109640957A (zh) * 2016-06-13 2019-04-16 梅哈里医学院 一氧化氮合酶途径对口腔健康的调节
WO2018007327A1 (en) * 2016-07-08 2018-01-11 Atonomics A/S A universal assay for determining the quantity of therapeutic monoclonal antibodies and their corresponding anti-drug-antibodies in samples
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
WO2018237379A2 (en) 2017-06-23 2018-12-27 Enzo Biochem, Inc. COMPOUNDS MODULATING THE PATH OF SPHINGOSINE FOR THE TREATMENT OF CANCERS
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
WO2019140265A1 (en) 2018-01-12 2019-07-18 President And Fellows Of Harvard College Trna synthetase inhibitors
WO2019140254A1 (en) * 2018-01-12 2019-07-18 President And Fellows Of Harvard College Multicyclic compounds and use of same for treating tuberculosis
EP3756012A1 (en) 2018-02-21 2020-12-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
WO2019210866A1 (zh) * 2018-05-02 2019-11-07 中山大学 SphK2抑制剂作为骨髓造血系统损伤后修复或治疗骨髓造血功能障碍的药物的用途
RU2732297C2 (ru) * 2018-11-14 2020-09-15 Общество с ограниченной ответственностью "Гурус БиоФарм" Производные нестероидных противовоспалительных средств
CN111233887A (zh) * 2018-11-28 2020-06-05 武汉武药科技有限公司 一种盐酸多佐胺中间体的合成工艺
KR20200085036A (ko) * 2019-01-04 2020-07-14 (주)아모레퍼시픽 아다만탄 카르복실산 벤질 아마이드 유도체 화합물 및 그를 포함하는 피부 미백용 조성물
CN113574068B (zh) * 2019-01-16 2024-07-23 艾宝奇生物工艺有限公司 诱导抗癌免疫应答的方法
RU2697409C1 (ru) * 2019-04-30 2019-08-14 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) 1-Адамантил-3-(((1R,4aS,10aR)-7-изопропил-1,4а-диметил-1,2,3,4,4а,9,10,10а-октагидрофенантрен-1-ил)метил)мочевина, проявляющая ингибирующее действие в отношении фермента тирозил-ДНК-фосфодиэстеразы 1 человека и увеличивающая активность темозоломида в отношении клеток глиобластомы
CN110330452A (zh) * 2019-06-12 2019-10-15 山东省医学科学院药物研究所（山东省抗衰老研究中心、山东省新技术制药研究所） 四氢吡咯烷类化合物或其药学上可接受的盐及其制备方法和应用
CN110483284B (zh) * 2019-08-26 2022-05-13 浙江工业大学 一种1-金刚烷甲酸-2-(取代苯甲酰氧基)乙酯类化合物及其合成方法和应用
BR112022017923A2 (pt) 2020-03-10 2022-10-18 Redhill Biopharma Ltd Tratamento de infecção por coronavírus
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN112336863A (zh) * 2020-11-26 2021-02-09 中山大学附属第八医院（深圳福田） S1p受体抑制剂在制备防治强直性脊柱炎产品中的应用
US11471448B2 (en) 2020-12-15 2022-10-18 Redhill Biopharma Ltd. Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657273A (en) * 1970-05-01 1972-04-18 Searle & Co Adamantane-1 3-dicarboxamides
US3663565A (en) * 1969-07-02 1972-05-16 Searle & Co Esters and amides of 3-phenyladamantane-1-carboxylic acid
SU451691A1 (ru) * 1973-03-27 1974-11-30 Киевский Ордена Ленина Политехнический Институт Им.50-Летия Великой Октябрьской Социалистической Революции Способ получени -метилстеариламидов адамантанкарбоновых кислот
US4053509A (en) * 1971-11-15 1977-10-11 Schering Corporation Substituted aryl and aralkyl amides
US4332806A (en) * 1979-11-12 1982-06-01 Sumitomo Chemical Company, Limited Antitumor and immunosuppresive 4-carbamoyl imidazolium-5-olate derivatives, pharmaceutical composition and production thereof
US4349552A (en) * 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
SU1574586A1 (ru) * 1988-06-20 1990-06-30 Институт Биоорганической Химии Ан Усср Способ получени замещенных бромом адамантан-1-карбоновых кислот
SU1367194A1 (ru) * 1984-03-16 1996-04-10 В.Ю. Ковтун Литиевая соль 1-адамантанкарбоновой кислоты, обладающая психостимулирующей активностью
US5595995A (en) * 1992-05-15 1997-01-21 British Technology Group Limited Pyridyl-propan-2-yl esters of 1-adamantane carboxylates
RU2197467C2 (ru) * 2000-11-09 2003-01-27 Институт нефтехимии и катализа АН РБ и УНЦ РАН Способ получения 1-хлор-3-ацетил- и 1,3-дихлор-5-ацетиладамантанов
US6649600B1 (en) * 1999-11-12 2003-11-18 Biogen, Inc. Adenosine receptor antagonists and methods of making and using the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352912A (en) * 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
BE791392A (fr) * 1971-11-15 1973-05-14 Scherico Ltd Aryl- et aralcoylamides substitues
CA1228346A (en) * 1983-10-07 1987-10-20 George M. Kramer Adamantylamine/long chain alkylamine catalysts and use in paraffin-olefin alkylation process
ATE94384T1 (de) * 1989-04-14 1993-10-15 Merz & Co Gmbh & Co Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie.
JP2511573B2 (ja) * 1990-11-29 1996-06-26 川崎製鉄株式会社 １―エチルアダマンタンの製造方法
JPH04322743A (ja) * 1991-04-24 1992-11-12 Kawasaki Steel Corp アルキルアダマンタン類の製造用触媒およびこれを用いたアルキルアダマンタン類の製造方法
JPH04330947A (ja) * 1991-05-02 1992-11-18 Kawasaki Steel Corp １−ビニルアダマンタン製造用触媒およびこれを用いた１−ビニルアダマンタンの製造方法
JP2001524468A (ja) * 1997-11-21 2001-12-04 エヌピーエス ファーマシューティカルズ インコーポレーテッド 中枢神経系疾患を治療するための代謝調節型グルタミン酸受容体アンタゴニスト
JP4271348B2 (ja) * 2000-06-16 2009-06-03 出光興産株式会社 １，３−アダマンタンジカルボン酸ジ−ｔｅｒｔ−ブチルの製造方法
AU2003245555A1 (en) * 2002-06-17 2003-12-31 The Pennsylvania State Research Foundation Sphingosine kinase inhibitors
US20040116479A1 (en) * 2002-10-04 2004-06-17 Fortuna Haviv Method of inhibiting angiogenesis
WO2004089415A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
JP4629657B2 (ja) * 2003-04-11 2011-02-09 ハイ・ポイント・ファーマスーティカルズ、エルエルシー １１β−ヒドロキシステロイドデヒドロゲナーゼ１型化活性化合物
WO2006048750A2 (en) 2004-11-02 2006-05-11 Pfizer Inc. Novel compounds of substituted and unsubstituted adamantyl amides
GB0506133D0 (en) 2005-03-24 2005-05-04 Sterix Ltd Compound
US8324237B2 (en) * 2005-05-20 2012-12-04 Smith Charles D Methods for the treatment and prevention of inflammatory diseases
US20060270631A1 (en) * 2005-05-26 2006-11-30 Smith Charles D Methods for the treatment and prevention of angiogenic diseases
US7338961B2 (en) * 2005-06-17 2008-03-04 Apogee Biotechnology Corporation Sphingosine kinase inhibitors
WO2010105183A1 (en) * 2009-03-12 2010-09-16 Apogee Biotechnology Corporation Sphingosine kinase inhibitor prodrugs
US20120122870A1 (en) * 2009-05-08 2012-05-17 Musc Foundation For Research Development Treatment Of Ischemia-Reperfusion Injury

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663565A (en) * 1969-07-02 1972-05-16 Searle & Co Esters and amides of 3-phenyladamantane-1-carboxylic acid
US3657273A (en) * 1970-05-01 1972-04-18 Searle & Co Adamantane-1 3-dicarboxamides
US4053509A (en) * 1971-11-15 1977-10-11 Schering Corporation Substituted aryl and aralkyl amides
SU451691A1 (ru) * 1973-03-27 1974-11-30 Киевский Ордена Ленина Политехнический Институт Им.50-Летия Великой Октябрьской Социалистической Революции Способ получени -метилстеариламидов адамантанкарбоновых кислот
US4349552A (en) * 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
US4332806A (en) * 1979-11-12 1982-06-01 Sumitomo Chemical Company, Limited Antitumor and immunosuppresive 4-carbamoyl imidazolium-5-olate derivatives, pharmaceutical composition and production thereof
SU1367194A1 (ru) * 1984-03-16 1996-04-10 В.Ю. Ковтун Литиевая соль 1-адамантанкарбоновой кислоты, обладающая психостимулирующей активностью
SU1574586A1 (ru) * 1988-06-20 1990-06-30 Институт Биоорганической Химии Ан Усср Способ получени замещенных бромом адамантан-1-карбоновых кислот
US5595995A (en) * 1992-05-15 1997-01-21 British Technology Group Limited Pyridyl-propan-2-yl esters of 1-adamantane carboxylates
US6649600B1 (en) * 1999-11-12 2003-11-18 Biogen, Inc. Adenosine receptor antagonists and methods of making and using the same
RU2197467C2 (ru) * 2000-11-09 2003-01-27 Институт нефтехимии и катализа АН РБ и УНЦ РАН Способ получения 1-хлор-3-ацетил- и 1,3-дихлор-5-ацетиладамантанов

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
V.V.Pozdnyakov et al, Synthesis and Reactivity of 3-R-1-Adamantyl Methyl Ketones. Russian Journal of Organic Chemistry, 2001, том 37, №9, с.1228-1231. M.A.El-Sherbeny, Adamantane Derivatives, Part II: Synthesis DNA Binding and Antitumor Evaluation. Medicinal Chemistry Research, 2002, том 11, №2, с.74-86. Макарова H.B. и др. Диметиловый эфир адамантаноилмалоновой кислоты - новый полупродукт в синтезе 1-ацетиладамантана. - Журнал Органической Химии, 1997, том 33, вып.8, с.1252. Козлов Н.Г. и др. Восстановительное аминирование 1-ацетиладамантана нитрилами. - Журнал Общей Химии, 1985, том LV, вып.3, с.609-613. Danilenko et al, Synthesis and Biological Activity of Adamantane Derivatives II. N-(1-Adamantoyl)anthranilic Acids. Pharmaceutical Chemistry Journal, 1973, том 7, №10, с.621-622. Safonova O.A. et al, Synthesis and Biological Activity of 5-(Adamant-1-yl)salicylic Acid, 3-(4-Hydroxyphenyl)adamantanecarboxylic Acid and Some of Their Derivatives. Pharmaceutical Chemistry Journal, 1989, т *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2529201C1 (ru) * 2013-06-18 2014-09-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный технический университет" (ВолгГТУ) Способ получения n-(2-гетероциклоалкил-1-илэтил)адамантан-2-аминов
RU2605698C1 (ru) * 2015-12-23 2016-12-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный технический университет" (ВолгГТУ) Производные 2-(адамант-2-ил)этиламина, обладающие потенциальной противовирусной активностью

Also Published As

Publication number Publication date
WO2006138660A3 (en) 2007-07-19
EP2314574A1 (en) 2011-04-27
US20120095004A1 (en) 2012-04-19
EP1904439A2 (en) 2008-04-02
IL187881A0 (en) 2008-03-20
CN101248041B (zh) 2013-11-20
WO2006138660A2 (en) 2006-12-28
BRPI0611966A2 (pt) 2012-08-28
KR20080027352A (ko) 2008-03-26
KR101386282B1 (ko) 2014-04-17
EP1904439B1 (en) 2014-11-26
ZA200800423B (en) 2008-10-29
BRPI0611966B1 (pt) 2022-05-03
IL187881A (en) 2013-08-29
US8063248B2 (en) 2011-11-22
ES2528451T3 (es) 2015-02-10
US8557800B2 (en) 2013-10-15
JP2008546714A (ja) 2008-12-25
MX2007015863A (es) 2008-04-02
CA2612338A1 (en) 2006-12-28
USRE49811E1 (en) 2024-01-23
US20060287317A1 (en) 2006-12-21
CA2612338C (en) 2015-02-03
AU2006261327B2 (en) 2012-07-05
RU2008100606A (ru) 2009-07-27
AU2006261327A1 (en) 2006-12-28
US7338961B2 (en) 2008-03-04
JP5368789B2 (ja) 2013-12-18
CN101248041A (zh) 2008-08-20
US20080167352A1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
RU2447060C2 (ru) Ингибиторы сфингозинкиназы
RU2388750C2 (ru) Ингибиторы фосфодиэстеразы 4, включая аналоги n-замещенного диариламина
JP6193922B2 (ja) ハロアルキルヘテロアリールベンズアミド化合物
RU2430101C2 (ru) Ингибиторы белок-тирозин-фосфатазы человека и способы применения
RU2403247C2 (ru) Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения
RU2472797C2 (ru) ПРОИЗВОДНЫЕ 2-[(2-(ФЕНИЛАМИНО)-1Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АМИНО]БЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IGF-1R ДЛЯ ЛЕЧЕНИЯ РАКА
RU2485131C2 (ru) Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой и содержащие их противогрибковые средства
ES2534392T3 (es) Inhibidores de la proteína tirosina fosfatasa humana y métodos de uso
RU2439068C2 (ru) Модуляторы mglur5
RU2008120850A (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
RU2005124359A (ru) Пирролилтиазолы и их применение в качестве обратных агонистов рецептора св 1
JP5896601B2 (ja) セラミド誘導体を用いる多発性嚢胞腎疾患の治療方法
CA2400141A1 (fr) Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
RU2004104625A (ru) Аналоги простагландинов в качестве агонистов рецептора ep4
RU2004127925A (ru) N3-алкилированные бензимидазольные производные в качестве ингибиторов мек
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
RU2005114021A (ru) Производные имидазола и их применение в качестве периферически-селективных ингибиторов дофамин-бета-гидролазы
JP2005527625A5 (ru)
RU2008138163A (ru) 4-фенилтиазол-5-карбоновые кислоты и амиды 4-фенилтиазол-5-карбоновой кислоты как ингибиторы polo-подобной киназы plk1
RU2008108898A (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
CA2407149A1 (en) Melanin-concentrating hormone antagonist
RU2007140737A (ru) Пиразолы
CA2618511A1 (en) Novel benzothiazolone derivatives
RU2011105151A (ru) Азольные соединения
RU2008119994A (ru) Ингибиторы калиевых каналов